Viva Biotech contributed to a round that will help Regenacy Pharmaceuticals push its diabetic peripheral neuropathy candidate into phase 2 trials.
Regenacy Pharmaceuticals, a US-based developer of diabetic neuropathy treatments, completed a $30m series A round yesterday that included drug discovery technology and services provider Viva Biotech Holdings.
Investment firm Cobro Ventures and venture capital firm Taiwania Capital Management co-led the round, which also featured Yonjin Venture, a subsidiary of financial holding company Yonjin Group, as well as 3E Bioventures Capital and Ta Ya Venture Holdings.
Founded in 2016, Regenacy is working on treatments for diabetic peripheral neuropathy, a condition where…
